Twist Bioscience (NASDAQ:TWST) CEO Emily Leproust Sells 4,887 Shares

Twist Bioscience Corporation (NASDAQ:TWST) CEO Emily Leproust sold 4,887 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $32.08, for a total transaction of $156,774.96. Following the sale, the chief executive officer owned 733,922 shares of the company’s stock, valued at approximately $23,544,217.76. This represents a 0.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Twist Bioscience Price Performance

TWST opened at $31.52 on Thursday. The company has a quick ratio of 3.60, a current ratio of 3.90 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 52-week low of $24.07 and a 52-week high of $55.33. The company has a 50 day moving average of $29.18 and a two-hundred day moving average of $31.74. The company has a market cap of $1.90 billion, a P/E ratio of -21.74 and a beta of 2.43.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.07. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. The company had revenue of $96.06 million during the quarter, compared to the consensus estimate of $95.52 million. On average, analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Barclays reduced their target price on shares of Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating on the stock in a research report on Thursday, October 2nd. Evercore ISI reduced their target price on shares of Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 7th. Stephens assumed coverage on shares of Twist Bioscience in a research report on Monday. They set an “overweight” rating and a $41.00 target price on the stock. Cowen reissued a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research report on Wednesday, October 8th. Ten research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $47.80.

Institutional Investors Weigh In On Twist Bioscience

A number of institutional investors and hedge funds have recently bought and sold shares of the business. ARK Investment Management LLC lifted its stake in Twist Bioscience by 2.5% during the second quarter. ARK Investment Management LLC now owns 6,400,441 shares of the company’s stock valued at $235,472,000 after purchasing an additional 158,846 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Twist Bioscience by 1.0% during the first quarter. Vanguard Group Inc. now owns 5,867,459 shares of the company’s stock worth $230,356,000 after buying an additional 60,276 shares in the last quarter. William Blair Investment Management LLC boosted its holdings in Twist Bioscience by 2.6% during the second quarter. William Blair Investment Management LLC now owns 3,906,604 shares of the company’s stock worth $143,724,000 after buying an additional 99,737 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Twist Bioscience by 186.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company’s stock worth $95,883,000 after buying an additional 1,588,587 shares in the last quarter. Finally, EdgePoint Investment Group Inc. boosted its holdings in Twist Bioscience by 114.3% during the second quarter. EdgePoint Investment Group Inc. now owns 2,385,942 shares of the company’s stock worth $87,779,000 after buying an additional 1,272,732 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.